Nature Communications (Oct 2017)
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
- Moshe Sade-Feldman,
- Yunxin J. Jiao,
- Jonathan H. Chen,
- Michael S. Rooney,
- Michal Barzily-Rokni,
- Jean-Pierre Eliane,
- Stacey L. Bjorgaard,
- Marc R. Hammond,
- Hans Vitzthum,
- Shauna M. Blackmon,
- Dennie T. Frederick,
- Mehlika Hazar-Rethinam,
- Brandon A. Nadres,
- Emily E. Van Seventer,
- Sachet A. Shukla,
- Keren Yizhak,
- John P. Ray,
- Daniel Rosebrock,
- Dimitri Livitz,
- Viktor Adalsteinsson,
- Gad Getz,
- Lyn M. Duncan,
- Bo Li,
- Ryan B. Corcoran,
- Donald P. Lawrence,
- Anat Stemmer-Rachamimov,
- Genevieve M. Boland,
- Dan A. Landau,
- Keith T. Flaherty,
- Ryan J. Sullivan,
- Nir Hacohen
Affiliations
- Moshe Sade-Feldman
- Department of Medicine, Massachusetts General Hospital Cancer Center
- Yunxin J. Jiao
- Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard
- Jonathan H. Chen
- Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard
- Michael S. Rooney
- Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard
- Michal Barzily-Rokni
- Department of Medicine, Massachusetts General Hospital Cancer Center
- Jean-Pierre Eliane
- Department of Pathology, Massachusetts General Hospital
- Stacey L. Bjorgaard
- Department of Medicine, Massachusetts General Hospital Cancer Center
- Marc R. Hammond
- Department of Medicine, Massachusetts General Hospital Cancer Center
- Hans Vitzthum
- Department of Medicine, Massachusetts General Hospital Cancer Center
- Shauna M. Blackmon
- Department of Medicine, Massachusetts General Hospital Cancer Center
- Dennie T. Frederick
- Department of Medicine, Massachusetts General Hospital Cancer Center
- Mehlika Hazar-Rethinam
- Department of Medicine, Massachusetts General Hospital Cancer Center
- Brandon A. Nadres
- Department of Medicine, Massachusetts General Hospital Cancer Center
- Emily E. Van Seventer
- Department of Medicine, Massachusetts General Hospital Cancer Center
- Sachet A. Shukla
- Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard
- Keren Yizhak
- Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard
- John P. Ray
- Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard
- Daniel Rosebrock
- Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard
- Dimitri Livitz
- Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard
- Viktor Adalsteinsson
- Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard
- Gad Getz
- Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard
- Lyn M. Duncan
- Department of Pathology, Massachusetts General Hospital
- Bo Li
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute
- Ryan B. Corcoran
- Department of Medicine, Massachusetts General Hospital Cancer Center
- Donald P. Lawrence
- Department of Medicine, Massachusetts General Hospital Cancer Center
- Anat Stemmer-Rachamimov
- Department of Pathology, Massachusetts General Hospital
- Genevieve M. Boland
- Department of Surgery, Massachusetts General Hospital
- Dan A. Landau
- Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard
- Keith T. Flaherty
- Department of Medicine, Massachusetts General Hospital Cancer Center
- Ryan J. Sullivan
- Department of Medicine, Massachusetts General Hospital Cancer Center
- Nir Hacohen
- Department of Medicine, Massachusetts General Hospital Cancer Center
- DOI
- https://doi.org/10.1038/s41467-017-01062-w
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 11
Abstract
Resistance to immune-checkpoint blockade often occurs in treated patients. Here, the authors demonstrate that B2M loss is a mechanism of primary and acquired resistance to therapies targeting CTLA4 or PD-1 in melanoma patients.
